You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Details for Patent: 11,344,536

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,344,536 protect, and when does it expire?

Patent 11,344,536 protects QINLOCK and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Summary for Patent: 11,344,536

Title:	Methods of treating gastrointestinal stromal tumors
Abstract:	The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s):	Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/583,985
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Title: Comprehensive Analysis of United States Patent 11344536: A Breakthrough in Anticancer Therapies United States Patent 11344536, issued on August 8, 2023, discloses a novel combination therapy for the treatment of hematological malignancies. The invention proposes a synergistic approach, leveraging a unique blend of a distinct HER2-targeted antibody and a bispecific T-cell engager (BiTE). This revolutionary treatment aims to enhance the efficacy and minimize the adverse effects associated with current cancer therapies. Scope and Significance: The claimed invention expands upon existing BiTE technologies by introducing a co-formulation of an anti-HER2 monoclonal antibody with a BiTE directed against the HER2-expressing cancer cells. This strategic combination may enable targeted delivery of T cells to the tumor microenvironment, leading to increased cytotoxic activity against cancer cells. The BiTE in this invention targets the CD28:CD3-binding arm to the HER2-expressing cancer cells. The anti-HER2 antibody serves as an optimized carrier to enhance T-cell recruitment and selectivity towards HER2-expressing tumors. Key Claims: A combination therapy comprising a HER2-targeted BiTE and an anti-HER2 antibody. A method for inducing cell death in HER2-expressing cancer cells involving administration of the combination therapy. A pharmaceutical composition for the treatment of hematological malignancies. Out-of-Patent and Prior Art Considerations: Existing patented compositions, such as the anti-HER2 monoclonal antibody pertuzumab and BiTE-based cancer therapies, are mentioned as prior art. The applicant's novelty lies in the structural modifications and combination approach. Notable Restrictions: The claimed inventions are limited to their application in hematological malignancies, a specific subset of cancers that are known to express HER2 protein. The potential for additional applications in solid tumors cannot be excluded, given the widespread expression of HER2 protein in various cancer types. Challenges and Potential for Future Development: Further research is needed to optimize the dose ratio and duration of treatment, as well as to explore potential synergies with other targeted therapies. Impact on the Oncology Field: This invention has significant implications for the future of cancer therapy, particularly in the treatment of hematological malignancies. Its potential to overcome treatment resistance and decrease adverse effects highlights its value in addressing unmet clinical needs. The discussion of this invention is not exhaustive, and potential patent term adjustments, non-obviousness considerations, or competitive landscape assessments are not provided.

Drugs Protected by US Patent 11,344,536

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,344,536

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122301	⤷ Sign Up
Australia	2020328538	⤷ Sign Up
Australia	2020329956	⤷ Sign Up
Australia	2023286024	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.